| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
NafaMostat (hydrochloride) manufacturers
|
| | NafaMostat (hydrochloride) Basic information |
| | NafaMostat (hydrochloride) Chemical Properties |
| Melting point | 264-266 °C | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | NafaMostat (hydrochloride) Usage And Synthesis |
| Uses | Nafamostat hydrochloride, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat hydrochloride has anticancer and antivirus effect. Nafamostat hydrochloride induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat hydrochloride can be used in the development of the pathological thickening of the arterial wall[1][2][3][4]. | | in vivo | Nafamostat hydrochloride (10 mg/kg, Intraperitoneal injection, once a day for 18 days) exhibits favourable antiviral effects against Zika virus (ZIKV) infection in A129 mice[3].
Nafamostat hydrochloride (0.5-2.0 mg/mL (dissolved in saline), Intraperitoneal injection, once a day for 7 consecutive days) has inhibitory effect on neointimal formation after balloon injury of the rat carotid wall[4]. | Animal Model: | A129 mice[3] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Exhibit delayed lethality and improved survival (40%). |
| Animal Model: | Balloon injury of the rat carotid wall [4] | | Dosage: | 0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline) | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Showed smaller ratios of the neointima/medial area.
Showed positive but reduced immunoreactivity of the cells in the neointimal. |
| | IC 50 | I-kappaBalpha | | References | [1] Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109(10): 2142-2153. DOI:10.1016/j.bmc.2023.117467
[2] Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94(5): 699-704. DOI:10.1002/ijc.1531
[3] Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325. DOI:10.1016/j.antiviral.2022.105325
[4] Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30(3): 644-650. DOI:10.1161/01.str.30.3.644 |
| | NafaMostat (hydrochloride) Preparation Products And Raw materials |
|